AVITA Medical Successfully Completes Equity Raising in Australia
AVITA Medical, Inc. (NASDAQ: RCEL), a recognized leader in transformative therapeutic acute wound care solutions, has announced the successful conclusion of its latest private placement. This equity raise aims to bolster the company's financial foundation and enhance its strategic capabilities.
Equity Raise Highlights and Details
The recent funding round involved the placement of about 17.2 million new CHESS Depositary Interests (New CDIs) on the Australian Securities Exchange (ASX). The issuance occurred at an appealing offer price of A$1.32 per New CDI, facilitating a total raise of approximately US$15 million (around A$23 million). This was made possible through the enthusiastic participation of both new and existing Australian shareholders.
Utilization of Proceeds
Funds generated from this placement will be strategically directed toward meeting working capital requirements and supporting the continuous growth of AVITA's therapeutic acute wound care portfolio. The management anticipates that these proceeds will secure operational stability until the company begins earning free cash flow, expected in the near future.
Management's Perspective
Jim Corbett, CEO of AVITA Medical, expressed confidence in the company's strategic direction and the remarkable support it has received from investors. He stated, "Our successful placement underscores the growing confidence in our vision, affirming the transformative potential of our therapeutic acute wound care solutions. We are excited to welcome our new shareholders and deeply appreciate the ongoing trust shown by our existing investors."
Action by Financial Partners
The exclusive management of the placement was led by MST Financial Services Pty Limited, a firm with considerable experience in capital markets and investment management, reflecting AVITA's commitment to aligning with capable partners for future endeavors.
Future Outlook and Next Steps
In the forthcoming period, AVITA Medical will proceed with the issuance of New CDIs as part of the placement, adhering to the regulations set out under ASX Listing Rule 7.1. The market eagerly anticipates the anticipated settlement of these new units, scheduled for early next week, which will pave the way for listing and trading on the ASX soon thereafter.
About AVITA Medical
AVITA Medical is renowned for its cutting-edge therapeutic acute wound care products. Central to its offerings is the RECELL® System, an innovative solution approved by the FDA for treating various wounds, including burns and traumatic injuries. The RECELL System utilizes a patient's own skin, enabling the creation of Spray-On Skin™ Cells that optimize healing and recovery times.
Global Reach and Regulatory Approvals
AVITA's technologies are not just limited to the U.S.; the RECELL System enjoys approvals for diverse applications globally, with registrations in Australia and Europe, as well as in Japan. Such advancements reinforce AVITA's commitment to establishing a strong international presence while providing effective wound care solutions.
Contact Information
For investor inquiries or media relations, please reach out to:
Ben Atkins
Phone: +1-805 341 1571
Email: investor@avitamedical.com, media@avitamedical.com
Frequently Asked Questions
What was the total amount raised by AVITA Medical?
AVITA Medical raised approximately US$15 million through this equity placement.
Who participated in the equity raise?
The equity raise included participation from both new and existing Australian shareholders.
What will the funds from the placement be used for?
The proceeds will be primarily for working capital requirements and supporting growth in the therapeutic acute wound care portfolio.
Who is the CEO of AVITA Medical?
Jim Corbett serves as the Chief Executive Officer of AVITA Medical.
What is the RECELL System?
The RECELL System is an innovative product from AVITA Medical designed to enhance wound healing by utilizing a patient's skin to produce Spray-On Skin™ Cells.
